<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title>BMC Cancer</journal-title><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2407-9-83</article-id><article-id pub-id-type="pmid">19291294</article-id><article-id pub-id-type="doi">10.1186/1471-2407-9-83</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>APRIL is overexpressed in cancer: link with tumor progression</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Moreaux</surname><given-names>J&#x000e9;r&#x000f4;me</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>jerome.moreaux@inserm.fr</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Veyrune</surname><given-names>Jean-Luc</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>jean-luc.veyrune@inserm.fr</email></contrib><contrib id="A3" contrib-type="author"><name><surname>De Vos</surname><given-names>John</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I2">2</xref><email>john.devos@inserm.fr</email></contrib><contrib id="A4" corresp="yes" contrib-type="author"><name><surname>Klein</surname><given-names>Bernard</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I2">2</xref><email>bernard.klein@inserm.fr</email></contrib></contrib-group><aff id="I1"><label>1</label>CHU Montpellier, Institute of Research in Biotherapy, Montpellier, France</aff><aff id="I2"><label>2</label>INSERM, U847, Montpellier, F-34197 France</aff><aff id="I3"><label>3</label>Universit&#x000e9; Montpellier1, UFR M&#x000e9;decine, Montpellier, France</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>16</day><month>3</month><year>2009</year></pub-date><volume>9</volume><fpage>83</fpage><lpage>83</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/9/83"/><history><date date-type="received"><day>28</day><month>7</month><year>2008</year></date><date date-type="accepted"><day>16</day><month>3</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Moreaux et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Moreaux et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Moreaux J&#x000e9;r&#x000f4;me jerome.moreaux@inserm.fr </dc:author><dc:title> APRIL is overexpressed in cancer: link with tumor progression </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>BMC Cancer 9(1): 83-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2407(2009)9:1&#x0003c;83&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2407</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>BAFF and APRIL share two receptors &#x02013; TACI and BCMA &#x02013; and BAFF binds to a third receptor, BAFF-R. Increased expression of BAFF and APRIL is noted in hematological malignancies. BAFF and APRIL are essential for the survival of normal and malignant B lymphocytes, and altered expression of BAFF or APRIL or of their receptors (BCMA, TACI, or BAFF-R) have been reported in various B-cell malignancies including B-cell non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Hodgkin's lymphoma, multiple myeloma, and Waldenstrom's macroglobulinemia.</p></sec><sec sec-type="methods"><title>Methods</title><p>We compared the expression of <italic>BAFF, APRIL, TACI and BAFF-R </italic>gene expression in 40 human tumor types &#x02013; brain, epithelial, lymphoid, germ cells &#x02013; to that of their normal tissue counterparts using publicly available gene expression data, including the Oncomine Cancer Microarray database.</p></sec><sec><title>Results</title><p>We found significant overexpression of <italic>TACI </italic>in multiple myeloma and thyroid carcinoma and an association between TACI expression and prognosis in lymphoma. Furthermore, <italic>BAFF and APRIL </italic>are overexpressed in many cancers and we show that <italic>APRIL </italic>expression is associated with tumor progression. We also found overexpression of at least one proteoglycan with heparan sulfate chains (HS), which are coreceptors for APRIL and TACI, in tumors where APRIL is either overexpressed or is a prognostic factor. APRIL could induce survival or proliferation directly through HS proteoglycans.</p></sec><sec><title>Conclusion</title><p>Taken together, these data suggest that APRIL is a potential prognostic factor for a large array of malignancies.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>APRIL and BAFF are two members of the TNF family. BAFF is a type II transmembrane protein that can be secreted after proteolytical cleavage from the cell membrane[<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. APRIL is processed intracellularly within the Golgi apparatus by a furin pro-protein convertase prior to secretion of the biologically active form[<xref ref-type="bibr" rid="B3">3</xref>]. APRIL can also be expressed as a cell surface fusion protein with TWEAK called TWE-PRIL[<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. Both ligands bind to TACI (transmembrane activator and CAML interactor) and BCMA (B-cell maturation antigen), two members of the TNFR family. BAFF binds additionally to BAFF receptor (BAFF-R). BAFF is involved in the survival of normal and malignant B cells and normal plasmablasts [<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B8">8</xref>]. APRIL is highly expressed in several tumor tissues, stimulates the growth of tumor cells[<xref ref-type="bibr" rid="B9">9</xref>] and promotes survival of normal plasmablasts and plasma cells[<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>].</p><p>Evidence has been presented that BAFF/APRIL contribute to malignancies of B cells and plasma cells: non-Hodgkin's lymphoma [<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B16">16</xref>], Hodgkin lymphoma[<xref ref-type="bibr" rid="B17">17</xref>], chronic lymphocytic leukemia[<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>], multiple myeloma [<xref ref-type="bibr" rid="B20">20</xref>-<xref ref-type="bibr" rid="B24">24</xref>] and Waldenstrom's macroglobulinemia[<xref ref-type="bibr" rid="B25">25</xref>].</p><p>Recombinant APRIL binds to several cell lines that do not express detectable mRNA for TACI and BCMA and proteoglycans were identified as APRIL-specific binding partners. This binding is mediated by heparan sulfate (HS) side chains and can be inhibited by heparin[<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref>]. Binding of APRIL to proteoglycans or BCMA/TACI involves different regions in APRIL. APRIL binds HS proteoglycans via the lysine-rich region in the N-terminal part, leaving the TNF-like region available to interact with others receptors. Blockade of APRIL/BAFF using human BCMA-Ig in nude mice inhibited the growth of a subcutaneously injected human lung carcinoma cell line (A549) and a human colon carcinoma cell line (HT29)[<xref ref-type="bibr" rid="B28">28</xref>]. These cell lines express APRIL, but not BAFF, TACI, BCMA or BAFF-R suggesting that HS proteoglycans could mediate the growth response to APRIL. However, BCMA-Fc leaves the APRIL binding HSPG domain intact. This blockade may suggest that the TNF-receptor binding domain is also necessary for activity, and that an additional APRIL-specific receptor might exist. B-cell lymphoma cells can bind large amount of APRIL secreted by neutrophils via proteoglycan binding and the high expression of APRIL in tumor lesion correlates with B-cell lymphoma aggressiveness[<xref ref-type="bibr" rid="B16">16</xref>]. More recently, Bischof <italic>et al </italic>demonstrated that TACI binds also HS proteoglycans like syndecan-1, syndecan-2 and syndecan-4 [<xref ref-type="bibr" rid="B29">29</xref>].</p><p>These data demonstrate that BAFF/APRIL are potent growth factors in B cell malignancies. Furthermore, APRIL could be implicated in tumor emergence and/or progression due to its ability to bind HS proteoglycans [<xref ref-type="bibr" rid="B26">26</xref>-<xref ref-type="bibr" rid="B28">28</xref>]. Therefore, we looked for the expression of <italic>BAFF, APRIL </italic>and of their receptors &#x02013; <italic>BAFF-R, BCMA</italic>, and <italic>TACI </italic>&#x02013; in various cancers, compared to their normal tissue or cell counterparts and in association with disease staging.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Databases</title><p>We used Oncomine Cancer Microarray database <ext-link ext-link-type="uri" xlink:href="http://www.oncomine.org"/>[<xref ref-type="bibr" rid="B30">30</xref>] and Amazonia database <ext-link ext-link-type="uri" xlink:href="http://amazonia.montp.inserm.fr/"/>[<xref ref-type="bibr" rid="B31">31</xref>] to study gene expression of <italic>BAFF, APRIL, BCMA, TACI, BAFF-R and HS proteoglycans </italic>genes in 40 human tumor types and their normal tissue counterparts as indicated in Table 1 (Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>). Only gene expression data obtained from a single study using the same methodology were compared. All data were log transformed, median centred per array, and the standard deviation was normalized to one per array[<xref ref-type="bibr" rid="B32">32</xref>].</p></sec><sec><title>Statistical analysis</title><p>Statistical comparisons were done with Mann-Whitney or Student t-tests.</p></sec></sec><sec><title>Results and Discussion</title><sec><title>BAFF is overexpressed in solid tumors</title><p>40 tumor types were investigated, including 36 solid tumors and 4 hematological tumors (Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>: Table 1). BAFF gene is overexpressed in 1/4 hematological tumors and in 5/36 solid tumors. BAFF is overexpressed in Hodgkin lymhoma compared to normal B cells (<italic>P </italic>= 4.9E-11), in Burkitt lymphoma compared to normal B cells (<italic>P </italic>= 5.4E-5), in diffuse large B cell lymphoma compared to normal B cells (<italic>P </italic>= .01) and in follicular lymphoma compared to normal B cells (<italic>P </italic>= 2E-6)[<xref ref-type="bibr" rid="B33">33</xref>]. Four independent studies have shown <italic>BAFF </italic>overexpression in glioblastoma compared to normal brain (<italic>P </italic>= 5.4E-13, <italic>P </italic>= 8E-6, <italic>P </italic>= 5.3E-5 and <italic>P </italic>= 0.008) [<xref ref-type="bibr" rid="B34">34</xref>-<xref ref-type="bibr" rid="B37">37</xref>] (Figure <xref ref-type="fig" rid="F1">1</xref>). Following stimulation with inflammatory cytokines, astrocytes <italic>in vitro </italic>produce high amounts of BAFF. <italic>BAFF </italic>is expressed in astrocytes in the normal human central nervous system and is strongly upregulated in activated astrocytes in the demyelinated lesions of multiple sclerosis[<xref ref-type="bibr" rid="B38">38</xref>]. BAFF secretion could be relevant in sustaining intrathecal B cell responses in autoimmune and infectious diseases of the central nervous system. Accordingly, <italic>BAFF </italic>expression is readily induced in the central nervous system by neurotrophic viruses and correlates with the recruitment of antibody-secreting cells[<xref ref-type="bibr" rid="B39">39</xref>]. The overexpression of BAFF in brain tumors could be linked to the accumulation of tumor cells or to inflammatory signals. Regarding other cancers, <italic>BAFF </italic>was found significantly overexpressed in breast carcinoma compared to normal breast (Richardson et al[<xref ref-type="bibr" rid="B40">40</xref>]; <italic>P </italic>= 2.4E-7), in esophageal adenocarcinoma compared to normal esophagus (Hao et al[<xref ref-type="bibr" rid="B41">41</xref>]; <italic>P </italic>= 3.7E-4), in clear cell renal cell carcinoma compared to normal kidney (Lenburg et al[<xref ref-type="bibr" rid="B42">42</xref>]; <italic>P </italic>= 2.1E-5) and in adult male germ cell tumor compared to normal testis (Korkola et al[<xref ref-type="bibr" rid="B43">43</xref>]; <italic>P </italic>= 8.3E-18).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>BAFF expression in various cancers</bold>. <italic>BAFF </italic>gene expression in normal brain, glioblastoma multiforme [<xref ref-type="bibr" rid="B34">34</xref>-<xref ref-type="bibr" rid="B37">37</xref>], normal breast, breast carcinoma[<xref ref-type="bibr" rid="B40">40</xref>], normal esophagus, esophageal adenocarcinoma[<xref ref-type="bibr" rid="B41">41</xref>], normal kidney, renal carcinoma[<xref ref-type="bibr" rid="B42">42</xref>], normal testis, adult male germ cell tumor[<xref ref-type="bibr" rid="B43">43</xref>], Hodgkin lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma and follicular lymphoma[<xref ref-type="bibr" rid="B33">33</xref>]. Data sets in a single panel were from the same study. GEP data are log transformed and normalized as previously described[<xref ref-type="bibr" rid="B32">32</xref>]. In brackets, are indicated the number of normal or tumor samples.</p></caption><graphic xlink:href="1471-2407-9-83-1"/></fig></sec><sec><title>APRIL is overexpressed in solid and hematological malignancies</title><p><italic>APRIL </italic>gene was overexpressed in 1/4 hematological and in 6/36 solid tumors in tumors (Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>: Table 1). <italic>APRIL </italic>was overexpressed in invasive bladder carcinoma compared to superficial bladder carcinoma in two independent studies (<italic>P </italic>= 3.3E-6 and <italic>P </italic>= 0.003)[<xref ref-type="bibr" rid="B44">44</xref>,<xref ref-type="bibr" rid="B45">45</xref>], in esophageal adenocarcinoma compared to normal esophagus in two independent studies (<italic>P </italic>= 3.7E-4 and <italic>P </italic>= 5.5E-4)[<xref ref-type="bibr" rid="B41">41</xref>,<xref ref-type="bibr" rid="B46">46</xref>], in glioblastoma compared to normal brain in two independent studies (<italic>P </italic>= 3.5E-4 and <italic>P </italic>= 0.006)[<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B36">36</xref>], in head and neck carcinoma compared to normal oral mucosa in two independent studies (<italic>P </italic>= 9.2E-10 and <italic>P </italic>= 0.009)[<xref ref-type="bibr" rid="B47">47</xref>,<xref ref-type="bibr" rid="B48">48</xref>], in diffuse large B cell lymphoma compared to normal lymph nodes (<italic>P </italic>= 7.6E-6)[<xref ref-type="bibr" rid="B49">49</xref>,<xref ref-type="bibr" rid="B50">50</xref>], in pancreatic adenocarcinoma compared to normal pancreas (Iocobuzio-Donahue et al[<xref ref-type="bibr" rid="B51">51</xref>]; <italic>P </italic>= 0.002) and in adult male germ cell tumor compared to normal testis (Korkola et al[<xref ref-type="bibr" rid="B43">43</xref>]; <italic>P </italic>= 1.6E-11) (Figure <xref ref-type="fig" rid="F2">2</xref>).</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>APRIL expression in various cancers</bold>. APRIL gene expression in normal bladder, bladder carcinoma[<xref ref-type="bibr" rid="B44">44</xref>,<xref ref-type="bibr" rid="B45">45</xref>], normal esophagus, esophageal adenocarcinoma[<xref ref-type="bibr" rid="B41">41</xref>,<xref ref-type="bibr" rid="B46">46</xref>], normal brain, glioblastoma multiform[<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B36">36</xref>], normal oral mucosa, head and neck carcinoma[<xref ref-type="bibr" rid="B47">47</xref>,<xref ref-type="bibr" rid="B48">48</xref>], normal B cell, lymphoma[<xref ref-type="bibr" rid="B49">49</xref>,<xref ref-type="bibr" rid="B50">50</xref>], normal pancreas, pancreatic adenocarcinoma[<xref ref-type="bibr" rid="B51">51</xref>], normal testis and adult male germ cell tumor[<xref ref-type="bibr" rid="B43">43</xref>]. Data sets in a single panel were from the same study. GEP data are log transformed and normalized as previously described[<xref ref-type="bibr" rid="B32">32</xref>]. In brackets, are indicated the number of normal or tumor samples.</p></caption><graphic xlink:href="1471-2407-9-83-2"/></fig><p>Recently, Schwaller <italic>et al</italic>[<xref ref-type="bibr" rid="B16">16</xref>] demonstrated that high <italic>APRIL </italic>expression in tumor lesions correlates with B-cell lymphoma aggressiveness. We found here that <italic>BAFF or APRIL </italic>expression could be also associated with tumor aggressiveness in other cancers (Figure <xref ref-type="fig" rid="F3">3</xref>). <italic>APRIL </italic>is significantly overexpressed in glioma grade 4 compared to glioma grade 3 (<italic>P </italic>= 3.1E-12) and in patients presenting glioma, dead at 3 years compared to patients alive at 3 years (<italic>P </italic>= 1.8E-4)[<xref ref-type="bibr" rid="B52">52</xref>] (Additional file <xref ref-type="supplementary-material" rid="S2">2</xref>). In bladder carcinoma, <italic>APRIL </italic>is overexpressed in patients dead at 3 years compared to patients alive at 3 years (<italic>P </italic>= .005)[<xref ref-type="bibr" rid="B53">53</xref>]. High tumor cell mass in breast cancer was also characterized by increased <italic>APRIL </italic>expression in two independent studies (<italic>P </italic>= .003 and <italic>P </italic>= .004)[<xref ref-type="bibr" rid="B54">54</xref>,<xref ref-type="bibr" rid="B55">55</xref>]. Stages II, III and IV cervical carcinoma showed an overexpression of <italic>APRIL </italic>compared to stage I (<italic>P </italic>= 0.003)[<xref ref-type="bibr" rid="B56">56</xref>] (Figure <xref ref-type="fig" rid="F3">3</xref>). On the contrary, BAFF overexpression was not associated with prognosis or tumor aggressiveness using online cancer gene expression analysis[<xref ref-type="bibr" rid="B32">32</xref>]. APRIL protein was detected in several human solid tumors[<xref ref-type="bibr" rid="B57">57</xref>] and normal epithelial cells[<xref ref-type="bibr" rid="B11">11</xref>]. Interestingly, APRIL protein expression was reported in larynx and oral cavity carcinoma, esophagus carcinoma, bladder carcinoma, breast cancer, pancreatic tumors, ovarian carcinoma, seminoma adenocarcinoma, glioblastoma multiforme and oligodendroglioma correlating with the results of our analysis[<xref ref-type="bibr" rid="B57">57</xref>,<xref ref-type="bibr" rid="B58">58</xref>]. In addition, neutrophils, present in the stroma of solid tumors, are major producers of APRIL [<xref ref-type="bibr" rid="B57">57</xref>] suggesting that APRIL overexpression may be due to infiltrating cells. Furthermore, APRIL that is produced in tumors is retained and accumulates in the tumor stroma though HSPG binding[<xref ref-type="bibr" rid="B57">57</xref>]. Nevertheless, an upregulation of APRIL protein (detected by in situ immunostaining) was shown to not alter disease-free and overall survivals of bladder, ovarian and head and neck carcinoma patients in retrospective studies[<xref ref-type="bibr" rid="B58">58</xref>]. We have identified here a significant overexpression of <italic>APRIL </italic>in patients with glioma or bladder carcinomas who were dead at 3 years compared to patients alive at 3 years. An explanation could be that a part of APRIL protein is quickly secreted and no more detectable by immunostaining. APRIL protein could also be used by tumor cells as a growth factor or released in the blood circulation.</p><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>Association between APRIL expression and aggressiveness in various cancers</bold>. APRIL gene expression in glioma[<xref ref-type="bibr" rid="B52">52</xref>], bladder carcinoma[<xref ref-type="bibr" rid="B53">53</xref>], breast carcinoma[<xref ref-type="bibr" rid="B54">54</xref>,<xref ref-type="bibr" rid="B55">55</xref>] and cervical carcinoma[<xref ref-type="bibr" rid="B56">56</xref>]. Data sets in a single panel were from the same study. GEP data are log transformed and normalized as previously described[<xref ref-type="bibr" rid="B32">32</xref>]. In brackets, are indicated the number of normal or tumor samples.</p></caption><graphic xlink:href="1471-2407-9-83-3"/></fig></sec><sec><title>TACI is overexpressed in hematological cancers</title><p>We have previously reported the relevance of Affymetrix microarrays to quantify <italic>BCMA </italic>and <italic>TACI </italic>expressions in MM since microarray data were validated by real time RT-PCR and flow cytometry[<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B59">59</xref>]. No differences in <italic>BCMA </italic>or <italic>BAFF-R </italic>expression between tumor cells and their normal counterparts could be found in the 40 cancer types available from Oncomine database. By contrast, a significant <italic>TACI </italic>overexpression was found in smoldering myeloma compared to normal plasma cells (<italic>Zhan et al</italic>[<xref ref-type="bibr" rid="B60">60</xref>]; <italic>P </italic>= 0.0009) and in thyroid carcinomas compared to normal thyroid (<italic>Huang et al</italic>[<xref ref-type="bibr" rid="B61">61</xref>]; <italic>P </italic>= 0.005) (Figure <xref ref-type="fig" rid="F4">4</xref>). Interestingly, we found that <italic>TACI </italic>expression is associated with a poor prognosis in Burkitt lymphoma. TACI is significantly overexpressed in patients presenting Burkitt lymphoma who were dead at five years compared to patients alive at five years (Dave et al[<xref ref-type="bibr" rid="B62">62</xref>]; <italic>P </italic>= 0.004) (Figure <xref ref-type="fig" rid="F4">4</xref>). Recently, it was described that APRIL-TACI interactions mediate non-Hodgkin lymphoma B-cell proliferation through Akt, regulating cyclin D1 and P21 expression[<xref ref-type="bibr" rid="B63">63</xref>]. These data suggest that TACI is the main receptor for BAFF/APRIL in lymphoma cells and is associated with a bad prognosis. TACI therefore represents a potential lymphoma therapeutic target.</p><fig position="float" id="F4"><label>Figure 4</label><caption><p><bold>TACI expression in various cancers</bold>. <italic>TACI </italic>gene expression in normal plasma cells, smoldering myeloma[<xref ref-type="bibr" rid="B60">60</xref>], normal thyroid, thyroid carcinoma[<xref ref-type="bibr" rid="B61">61</xref>] and lymphoma[<xref ref-type="bibr" rid="B62">62</xref>]. Data sets in a single panel were from the same study. GEP data are log transformed and normalized as previously described[<xref ref-type="bibr" rid="B32">32</xref>]. In brackets, are indicated the number of normal or tumor samples.</p></caption><graphic xlink:href="1471-2407-9-83-4"/></fig></sec><sec><title>Correlations between APRIL and heparan sulfate chain proteoglycans overexpression in tumor cells</title><p>Receptors for BAFF and APRIL are expressed exclusively by lymphoid cells. APRIL can bind and promote tumor-cell proliferation of several cell lines that do not express detectable mRNA for TACI and BCMA[<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B64">64</xref>,<xref ref-type="bibr" rid="B65">65</xref>]. Ingold <italic>et al </italic>and Hendriks <italic>at al </italic>identified proteoglycans as the APRIL-non specific binding partners. This binding is mediated by HS side chains and can be inhibited by heparin[<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref>]. Only APRIL expression was associated with a bad prognosis in several cancers. APRIL could sustain the survival of malignant cells directly through HS proteoglycans that can deliver signals through their intracellular tails upon binding to ligands[<xref ref-type="bibr" rid="B66">66</xref>,<xref ref-type="bibr" rid="B67">67</xref>].</p><p>Eleven HS proteoglycans has been identified so far &#x02013; syndecan 1&#x02013;4, glypican 1&#x02013;6, CD44 isoforms containing the alternatively spliced exon v3 &#x02013; and their gene expression can be evaluated by microarrays[<xref ref-type="bibr" rid="B68">68</xref>] (see Additional file <xref ref-type="supplementary-material" rid="S3">3</xref>). Interestingly, at least one HS proteoglycan gene was significantly overexpressed in cancers presenting an overexpression of APRIL compared to their normal counterparts (see Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>). A similar observation was made for cancers showing an association between <italic>APRIL </italic>expression and the evolution of the disease (see Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>).</p><p>HS proteoglycans regulate growth factor signaling, cytoskeleton organization, cell adhesion and migration[<xref ref-type="bibr" rid="B69">69</xref>]. HS proteoglycans are implicated in solid tumor development[<xref ref-type="bibr" rid="B70">70</xref>,<xref ref-type="bibr" rid="B71">71</xref>]. Syndecan-1 is absolutely required for the development of mammary tumors driven by the transgenic expression of the proto-oncogene Wnt-1 in mice[<xref ref-type="bibr" rid="B72">72</xref>]. The important role of HS proteoglycans is attributed in part to its highly negative electric potential, making it able to bind numerous proteins and to function as a coreceptor. However as APRIL activates cells that do not express TACI or BCMA, a direct signaling by the HS proteoglycans core protein is possible as already shown [<xref ref-type="bibr" rid="B66">66</xref>]. It may explain the overexpression of APRIL in association with disease aggressiveness in solid tumors which do not express BCMA or TACI. Nevertheless, additional studies are required to understand the exact role of APRIL in solid tumors, the existence of a signaling linked to the interaction of APRIL with HS proteoglycans and the possible existence of a receptor specific to APRIL not yet identified.</p></sec></sec><sec><title>Conclusion</title><p>The analysis reported here demonstrates that <italic>APRIL </italic>mRNA is overexpressed in at least 8 cancers compared to their normal counterparts, and within a given tumor category, is associated with a bad prognosis. These observations emphasize the interest using BAFF/APRIL inhibitors in the treatment of patients with cancers. We recently completed a phase I-II clinical trial of Atacicept TACI-Fc inhibitor showing the feasibility and safety of this targeting in multiple myeloma (submitted data). Heparin could be also useful in blocking APRIL binding to surface HS proteoglycan. Of note, we found here always one HS proteoglycan gene overexpressed in tumors that also highly expressed APRIL. A recent study reported that a brief course of subcutaneous low molecular weight heparin favorably influences the survival in patients with advanced malignancy and deserves additional clinical evaluation[<xref ref-type="bibr" rid="B73">73</xref>]. Thus, the targeting of APRIL or its interaction with HS proteoglycans may be promising in a large number of cancers.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>JM designed research, performed the analyses and wrote the paper. JLV and JDV have been involved in drafting and reviewing of the manuscript. BK is the senior investigator who designed research and wrote the paper. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/9/83/prepub"/></p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p><bold>Expression of <italic>BAFF, APRIL, TACI, BAFF-R </italic>and <italic>heparan sulfate proteoglycans </italic>in human tumor types to that of their normal tissue counterparts using publicly available gene expression data, including the Oncomine Cancer Microarray database.</bold></p></caption><media xlink:href="1471-2407-9-83-S1.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S2"><caption><title>Additional file 2</title><p><bold>Classification of cancers included in the analysis.</bold></p></caption><media xlink:href="1471-2407-9-83-S2.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S3"><caption><title>Additional file 3</title><p><bold>Gene expression profile of Syndecan 1&#x02013;4 and glypican 1&#x02013;6 was determined using Oncomine Cancer Microarray database in bladder carcinoma, esophagus adenocarcinoma, brain tumors, breast cancer, head and neck tumors, lymphoma, pancreatic adenocarcinoma and adult male germ cell tumors presenting an overexpression of APRIL or an association with a bad prognosis or tumor progression.</bold></p></caption><media xlink:href="1471-2407-9-83-S3.pdf" mimetype="application" mime-subtype="pdf"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>This work was supported by grants from the Ligue Nationale Contre le Cancer (&#x000e9;quipe labellis&#x000e9;e 2006), Paris, France, from INCA (n&#x000b0;R07001FN) and from MSCNET European strep (N&#x000b0;E06005FF).</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nardelli</surname><given-names>B</given-names></name><name><surname>Belvedere</surname><given-names>O</given-names></name><name><surname>Roschke</surname><given-names>V</given-names></name><name><surname>Moore</surname><given-names>PA</given-names></name><name><surname>Olsen</surname><given-names>HS</given-names></name><name><surname>Migone</surname><given-names>TS</given-names></name><name><surname>Sosnovtseva</surname><given-names>S</given-names></name><name><surname>Carrell</surname><given-names>JA</given-names></name><name><surname>Feng</surname><given-names>P</given-names></name><name><surname>Giri</surname><given-names>JG</given-names></name><etal></etal></person-group><article-title>Synthesis and release of B-lymphocyte stimulator from myeloid cells</article-title><source>Blood</source><year>2001</year><volume>97</volume><fpage>198</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">11133761</pub-id><pub-id pub-id-type="doi">10.1182/blood.V97.1.198</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>P</given-names></name><name><surname>MacKay</surname><given-names>F</given-names></name><name><surname>Steiner</surname><given-names>V</given-names></name><name><surname>Hofmann</surname><given-names>K</given-names></name><name><surname>Bodmer</surname><given-names>JL</given-names></name><name><surname>Holler</surname><given-names>N</given-names></name><name><surname>Ambrose</surname><given-names>C</given-names></name><name><surname>Lawton</surname><given-names>P</given-names></name><name><surname>Bixler</surname><given-names>S</given-names></name><name><surname>Acha-Orbea</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth</article-title><source>J Exp Med</source><year>1999</year><volume>189</volume><fpage>1747</fpage><lpage>1756</lpage><pub-id pub-id-type="pmid">10359578</pub-id><pub-id pub-id-type="doi">10.1084/jem.189.11.1747</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Fraga</surname><given-names>M</given-names></name><name><surname>Fernandez</surname><given-names>R</given-names></name><name><surname>Albar</surname><given-names>JP</given-names></name><name><surname>Hahne</surname><given-names>M</given-names></name></person-group><article-title>Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase</article-title><source>EMBO Rep</source><year>2001</year><volume>2</volume><fpage>945</fpage><lpage>951</lpage><pub-id pub-id-type="pmid">11571266</pub-id><pub-id pub-id-type="doi">10.1093/embo-reports/kve198</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kolfschoten</surname><given-names>GM</given-names></name><name><surname>Pradet-Balade</surname><given-names>B</given-names></name><name><surname>Hahne</surname><given-names>M</given-names></name><name><surname>Medema</surname><given-names>JP</given-names></name></person-group><article-title>TWE-PRIL; a fusion protein of TWEAK and APRIL</article-title><source>Biochem Pharmacol</source><year>2003</year><volume>66</volume><fpage>1427</fpage><lpage>1432</lpage><pub-id pub-id-type="pmid">14555217</pub-id><pub-id pub-id-type="doi">10.1016/S0006-2952(03)00493-3</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pradet-Balade</surname><given-names>B</given-names></name><name><surname>Medema</surname><given-names>JP</given-names></name><name><surname>Lopez-Fraga</surname><given-names>M</given-names></name><name><surname>Lozano</surname><given-names>JC</given-names></name><name><surname>Kolfschoten</surname><given-names>GM</given-names></name><name><surname>Picard</surname><given-names>A</given-names></name><name><surname>Martinez</surname><given-names>AC</given-names></name><name><surname>Garcia-Sanz</surname><given-names>JA</given-names></name><name><surname>Hahne</surname><given-names>M</given-names></name></person-group><article-title>An endogenous hybrid mRNA encodes TWE-PRIL, a functional cell surface TWEAK-APRIL fusion protein</article-title><source>Embo J</source><year>2002</year><volume>21</volume><fpage>5711</fpage><lpage>5720</lpage><pub-id pub-id-type="pmid">12411489</pub-id><pub-id pub-id-type="doi">10.1093/emboj/cdf565</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Avery</surname><given-names>DT</given-names></name><name><surname>Kalled</surname><given-names>SL</given-names></name><name><surname>Ellyard</surname><given-names>JI</given-names></name><name><surname>Ambrose</surname><given-names>C</given-names></name><name><surname>Bixler</surname><given-names>SA</given-names></name><name><surname>Thien</surname><given-names>M</given-names></name><name><surname>Brink</surname><given-names>R</given-names></name><name><surname>Mackay</surname><given-names>F</given-names></name><name><surname>Hodgkin</surname><given-names>PD</given-names></name><name><surname>Tangye</surname><given-names>SG</given-names></name></person-group><article-title>BAFF selectively enhances the survival of plasmablasts generated from human memory B cells</article-title><source>J Clin Invest</source><year>2003</year><volume>112</volume><fpage>286</fpage><lpage>297</lpage><pub-id pub-id-type="pmid">12865416</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bossen</surname><given-names>C</given-names></name><name><surname>Cachero</surname><given-names>TG</given-names></name><name><surname>Tardivel</surname><given-names>A</given-names></name><name><surname>Ingold</surname><given-names>K</given-names></name><name><surname>Willen</surname><given-names>L</given-names></name><name><surname>Dobles</surname><given-names>M</given-names></name><name><surname>Scott</surname><given-names>ML</given-names></name><name><surname>Maquelin</surname><given-names>A</given-names></name><name><surname>Belnoue</surname><given-names>E</given-names></name><name><surname>Siegrist</surname><given-names>CA</given-names></name><etal></etal></person-group><article-title>TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts</article-title><source>Blood</source><year>2008</year><volume>111</volume><fpage>1004</fpage><lpage>1012</lpage><pub-id pub-id-type="pmid">17942754</pub-id><pub-id pub-id-type="doi">10.1182/blood-2007-09-110874</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mackay</surname><given-names>F</given-names></name><name><surname>Schneider</surname><given-names>P</given-names></name><name><surname>Rennert</surname><given-names>P</given-names></name><name><surname>Browning</surname><given-names>J</given-names></name></person-group><article-title>BAFF AND APRIL: A Tutorial on B Cell Survival</article-title><source>Annu Rev Immunol</source><year>2003</year><volume>21</volume><fpage>231</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">12427767</pub-id><pub-id pub-id-type="doi">10.1146/annurev.immunol.21.120601.141152</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hahne</surname><given-names>M</given-names></name><name><surname>Kataoka</surname><given-names>T</given-names></name><name><surname>Schroter</surname><given-names>M</given-names></name><name><surname>Hofmann</surname><given-names>K</given-names></name><name><surname>Irmler</surname><given-names>M</given-names></name><name><surname>Bodmer</surname><given-names>JL</given-names></name><name><surname>Schneider</surname><given-names>P</given-names></name><name><surname>Bornand</surname><given-names>T</given-names></name><name><surname>Holler</surname><given-names>N</given-names></name><name><surname>French</surname><given-names>LE</given-names></name><etal></etal></person-group><article-title>APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth</article-title><source>J Exp Med</source><year>1998</year><volume>188</volume><fpage>1185</fpage><lpage>1190</lpage><pub-id pub-id-type="pmid">9743536</pub-id><pub-id pub-id-type="doi">10.1084/jem.188.6.1185</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Belnoue</surname><given-names>E</given-names></name><name><surname>Pihlgren</surname><given-names>M</given-names></name><name><surname>McGaha</surname><given-names>TL</given-names></name><name><surname>Tougne</surname><given-names>C</given-names></name><name><surname>Rochat</surname><given-names>AF</given-names></name><name><surname>Bossen</surname><given-names>C</given-names></name><name><surname>Schneider</surname><given-names>P</given-names></name><name><surname>Huard</surname><given-names>B</given-names></name><name><surname>Lambert</surname><given-names>PH</given-names></name><name><surname>Siegrist</surname><given-names>CA</given-names></name></person-group><article-title>APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early life bone marrow stromal cells</article-title><source>Blood</source><year>2008</year><volume>111</volume><fpage>2755</fpage><lpage>2764</lpage><pub-id pub-id-type="pmid">18180376</pub-id><pub-id pub-id-type="doi">10.1182/blood-2007-09-110858</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huard</surname><given-names>B</given-names></name><name><surname>McKee</surname><given-names>T</given-names></name><name><surname>Bosshard</surname><given-names>C</given-names></name><name><surname>Durual</surname><given-names>S</given-names></name><name><surname>Matthes</surname><given-names>T</given-names></name><name><surname>Myit</surname><given-names>S</given-names></name><name><surname>Donze</surname><given-names>O</given-names></name><name><surname>Frossard</surname><given-names>C</given-names></name><name><surname>Chizzolini</surname><given-names>C</given-names></name><name><surname>Favre</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa</article-title><source>J Clin Invest</source><year>2008</year><volume>118</volume><fpage>2887</fpage><lpage>2895</lpage><pub-id pub-id-type="pmid">18618015</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Briones</surname><given-names>J</given-names></name><name><surname>Timmerman</surname><given-names>JM</given-names></name><name><surname>Hilbert</surname><given-names>DM</given-names></name><name><surname>Levy</surname><given-names>R</given-names></name></person-group><article-title>BLyS and BLyS receptor expression in non-Hodgkin's lymphoma</article-title><source>Exp Hematol</source><year>2002</year><volume>30</volume><fpage>135</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">11823048</pub-id><pub-id pub-id-type="doi">10.1016/S0301-472X(01)00774-3</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>L</given-names></name><name><surname>Lin-Lee</surname><given-names>YC</given-names></name><name><surname>Pham</surname><given-names>LV</given-names></name><name><surname>Tamayo</surname><given-names>A</given-names></name><name><surname>Yoshimura</surname><given-names>L</given-names></name><name><surname>Ford</surname><given-names>RJ</given-names></name></person-group><article-title>Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas</article-title><source>Blood</source><year>2006</year><volume>107</volume><fpage>4540</fpage><lpage>4548</lpage><pub-id pub-id-type="pmid">16497967</pub-id><pub-id pub-id-type="doi">10.1182/blood-2005-10-4042</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>B</given-names></name><name><surname>Chadburn</surname><given-names>A</given-names></name><name><surname>Jou</surname><given-names>E</given-names></name><name><surname>Schattner</surname><given-names>EJ</given-names></name><name><surname>Knowles</surname><given-names>DM</given-names></name><name><surname>Cerutti</surname><given-names>A</given-names></name></person-group><article-title>Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL</article-title><source>J Immunol</source><year>2004</year><volume>172</volume><fpage>3268</fpage><lpage>3279</lpage><pub-id pub-id-type="pmid">14978135</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Novak</surname><given-names>AJ</given-names></name><name><surname>Grote</surname><given-names>DM</given-names></name><name><surname>Stenson</surname><given-names>M</given-names></name><name><surname>Ziesmer</surname><given-names>SC</given-names></name><name><surname>Witzig</surname><given-names>TE</given-names></name><name><surname>Habermann</surname><given-names>TM</given-names></name><name><surname>Harder</surname><given-names>B</given-names></name><name><surname>Ristow</surname><given-names>KM</given-names></name><name><surname>Bram</surname><given-names>RJ</given-names></name><name><surname>Jelinek</surname><given-names>DF</given-names></name><etal></etal></person-group><article-title>Expression of BLyS and Its Receptors in B-Cell Non-Hodgkin Lymphoma: Correlation With Disease Activity and Patient Outcome</article-title><source>Blood</source><year>2004</year><volume>104</volume><fpage>2247</fpage><lpage>2253</lpage><pub-id pub-id-type="pmid">15251985</pub-id><pub-id pub-id-type="doi">10.1182/blood-2004-02-0762</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schwaller</surname><given-names>J</given-names></name><name><surname>Schneider</surname><given-names>P</given-names></name><name><surname>Mhawech-Fauceglia</surname><given-names>P</given-names></name><name><surname>McKee</surname><given-names>T</given-names></name><name><surname>Myit</surname><given-names>S</given-names></name><name><surname>Matthes</surname><given-names>T</given-names></name><name><surname>Tschopp</surname><given-names>J</given-names></name><name><surname>Donze</surname><given-names>O</given-names></name><name><surname>Le Gal</surname><given-names>FA</given-names></name><name><surname>Huard</surname><given-names>B</given-names></name></person-group><article-title>Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness</article-title><source>Blood</source><year>2007</year><volume>109</volume><fpage>331</fpage><lpage>338</lpage><pub-id pub-id-type="pmid">17190854</pub-id><pub-id pub-id-type="doi">10.1182/blood-2006-02-001800</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chiu</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>He</surname><given-names>B</given-names></name><name><surname>Dillon</surname><given-names>SR</given-names></name><name><surname>Gross</surname><given-names>JA</given-names></name><name><surname>Sievers</surname><given-names>E</given-names></name><name><surname>Qiao</surname><given-names>X</given-names></name><name><surname>Santini</surname><given-names>P</given-names></name><name><surname>Hyjek</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name><etal></etal></person-group><article-title>Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL</article-title><source>Blood</source><year>2007</year><volume>109</volume><fpage>729</fpage><lpage>739</lpage><pub-id pub-id-type="pmid">16960154</pub-id><pub-id pub-id-type="doi">10.1182/blood-2006-04-015958</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kern</surname><given-names>C</given-names></name><name><surname>Cornuel</surname><given-names>JF</given-names></name><name><surname>Billard</surname><given-names>C</given-names></name><name><surname>Tang</surname><given-names>R</given-names></name><name><surname>Rouillard</surname><given-names>D</given-names></name><name><surname>Stenou</surname><given-names>V</given-names></name><name><surname>Defrance</surname><given-names>T</given-names></name><name><surname>Ajchenbaum-Cymbalista</surname><given-names>F</given-names></name><name><surname>Simonin</surname><given-names>PY</given-names></name><name><surname>Feldblum</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway</article-title><source>Blood</source><year>2004</year><volume>103</volume><fpage>679</fpage><lpage>688</lpage><pub-id pub-id-type="pmid">14504101</pub-id><pub-id pub-id-type="doi">10.1182/blood-2003-02-0540</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Novak</surname><given-names>AJ</given-names></name><name><surname>Bram</surname><given-names>RJ</given-names></name><name><surname>Kay</surname><given-names>NE</given-names></name><name><surname>Jelinek</surname><given-names>DF</given-names></name></person-group><article-title>Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival</article-title><source>Blood</source><year>2002</year><volume>100</volume><fpage>2973</fpage><lpage>2979</lpage><pub-id pub-id-type="pmid">12351410</pub-id><pub-id pub-id-type="doi">10.1182/blood-2002-02-0558</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moreaux</surname><given-names>J</given-names></name><name><surname>Cremer</surname><given-names>FW</given-names></name><name><surname>Reme</surname><given-names>T</given-names></name><name><surname>Raab</surname><given-names>M</given-names></name><name><surname>Mahtouk</surname><given-names>K</given-names></name><name><surname>Kaukel</surname><given-names>P</given-names></name><name><surname>Pantesco</surname><given-names>V</given-names></name><name><surname>De Vos</surname><given-names>J</given-names></name><name><surname>Jourdan</surname><given-names>E</given-names></name><name><surname>Jauch</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature</article-title><source>Blood</source><year>2005</year><volume>106</volume><fpage>1021</fpage><lpage>1030</lpage><pub-id pub-id-type="pmid">15827134</pub-id><pub-id pub-id-type="doi">10.1182/blood-2004-11-4512</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moreaux</surname><given-names>J</given-names></name><name><surname>Hose</surname><given-names>D</given-names></name><name><surname>Jourdan</surname><given-names>M</given-names></name><name><surname>Reme</surname><given-names>T</given-names></name><name><surname>Hundemer</surname><given-names>M</given-names></name><name><surname>Moos</surname><given-names>M</given-names></name><name><surname>Robert</surname><given-names>N</given-names></name><name><surname>Moine</surname><given-names>P</given-names></name><name><surname>De Vos</surname><given-names>J</given-names></name><name><surname>Goldschmidt</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines</article-title><source>Haematologica</source><year>2007</year><volume>92</volume><fpage>803</fpage><lpage>811</lpage><pub-id pub-id-type="pmid">17550853</pub-id><pub-id pub-id-type="doi">10.3324/haematol.10574</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moreaux</surname><given-names>J</given-names></name><name><surname>Legouffe</surname><given-names>E</given-names></name><name><surname>Jourdan</surname><given-names>E</given-names></name><name><surname>Quittet</surname><given-names>P</given-names></name><name><surname>Reme</surname><given-names>T</given-names></name><name><surname>Lugagne</surname><given-names>C</given-names></name><name><surname>Moine</surname><given-names>P</given-names></name><name><surname>Rossi</surname><given-names>JF</given-names></name><name><surname>Klein</surname><given-names>B</given-names></name><name><surname>Tarte</surname><given-names>K</given-names></name></person-group><article-title>BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone</article-title><source>Blood</source><year>2004</year><volume>103</volume><fpage>3148</fpage><lpage>3157</lpage><pub-id pub-id-type="pmid">15070697</pub-id><pub-id pub-id-type="doi">10.1182/blood-2003-06-1984</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Novak</surname><given-names>AJ</given-names></name><name><surname>Darce</surname><given-names>JR</given-names></name><name><surname>Arendt</surname><given-names>BK</given-names></name><name><surname>Harder</surname><given-names>B</given-names></name><name><surname>Henderson</surname><given-names>K</given-names></name><name><surname>Kindsvogel</surname><given-names>W</given-names></name><name><surname>Gross</surname><given-names>JA</given-names></name><name><surname>Greipp</surname><given-names>PR</given-names></name><name><surname>Jelinek</surname><given-names>DF</given-names></name></person-group><article-title>Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival</article-title><source>Blood</source><year>2004</year><volume>103</volume><fpage>689</fpage><lpage>694</lpage><pub-id pub-id-type="pmid">14512299</pub-id><pub-id pub-id-type="doi">10.1182/blood-2003-06-2043</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yaccoby</surname><given-names>S</given-names></name><name><surname>Pennisi</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Dillon</surname><given-names>SR</given-names></name><name><surname>Zhan</surname><given-names>F</given-names></name><name><surname>Barlogie</surname><given-names>B</given-names></name><name><surname>Shaughnessy</surname><given-names>JD</given-names><suffix>Jr</suffix></name></person-group><article-title>Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts</article-title><source>Leukemia</source><year>2008</year><volume>22</volume><fpage>406</fpage><lpage>413</lpage><pub-id pub-id-type="pmid">18046446</pub-id><pub-id pub-id-type="doi">10.1038/sj.leu.2405048</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elsawa</surname><given-names>SF</given-names></name><name><surname>Novak</surname><given-names>AJ</given-names></name><name><surname>Grote</surname><given-names>DM</given-names></name><name><surname>Ziesmer</surname><given-names>SC</given-names></name><name><surname>Witzig</surname><given-names>TE</given-names></name><name><surname>Kyle</surname><given-names>RA</given-names></name><name><surname>Dillon</surname><given-names>SR</given-names></name><name><surname>Harder</surname><given-names>B</given-names></name><name><surname>Gross</surname><given-names>JA</given-names></name><name><surname>Ansell</surname><given-names>SM</given-names></name></person-group><article-title>B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia</article-title><source>Blood</source><year>2006</year><volume>107</volume><fpage>2882</fpage><lpage>2888</lpage><pub-id pub-id-type="pmid">16304043</pub-id><pub-id pub-id-type="doi">10.1182/blood-2005-09-3552</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hendriks</surname><given-names>J</given-names></name><name><surname>Planelles</surname><given-names>L</given-names></name><name><surname>de Jong-Odding</surname><given-names>J</given-names></name><name><surname>Hardenberg</surname><given-names>G</given-names></name><name><surname>Pals</surname><given-names>ST</given-names></name><name><surname>Hahne</surname><given-names>M</given-names></name><name><surname>Spaargaren</surname><given-names>M</given-names></name><name><surname>Medema</surname><given-names>JP</given-names></name></person-group><article-title>Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation</article-title><source>Cell Death Differ</source><year>2005</year><volume>12</volume><fpage>637</fpage><lpage>648</lpage><pub-id pub-id-type="pmid">15846369</pub-id><pub-id pub-id-type="doi">10.1038/sj.cdd.4401647</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ingold</surname><given-names>K</given-names></name><name><surname>Zumsteg</surname><given-names>A</given-names></name><name><surname>Tardivel</surname><given-names>A</given-names></name><name><surname>Huard</surname><given-names>B</given-names></name><name><surname>Steiner</surname><given-names>QG</given-names></name><name><surname>Cachero</surname><given-names>TG</given-names></name><name><surname>Qiang</surname><given-names>F</given-names></name><name><surname>Gorelik</surname><given-names>L</given-names></name><name><surname>Kalled</surname><given-names>SL</given-names></name><name><surname>Acha-Orbea</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Identification of proteoglycans as the APRIL-specific binding partners</article-title><source>J Exp Med</source><year>2005</year><volume>201</volume><fpage>1375</fpage><lpage>1383</lpage><pub-id pub-id-type="pmid">15851487</pub-id><pub-id pub-id-type="doi">10.1084/jem.20042309</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rennert</surname><given-names>P</given-names></name><name><surname>Schneider</surname><given-names>P</given-names></name><name><surname>Cachero</surname><given-names>TG</given-names></name><name><surname>Thompson</surname><given-names>J</given-names></name><name><surname>Trabach</surname><given-names>L</given-names></name><name><surname>Hertig</surname><given-names>S</given-names></name><name><surname>Holler</surname><given-names>N</given-names></name><name><surname>Qian</surname><given-names>F</given-names></name><name><surname>Mullen</surname><given-names>C</given-names></name><name><surname>Strauch</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth</article-title><source>J Exp Med</source><year>2000</year><volume>192</volume><fpage>1677</fpage><lpage>1684</lpage><pub-id pub-id-type="pmid">11104810</pub-id><pub-id pub-id-type="doi">10.1084/jem.192.11.1677</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bischof</surname><given-names>D</given-names></name><name><surname>Elsawa</surname><given-names>SF</given-names></name><name><surname>Mantchev</surname><given-names>G</given-names></name><name><surname>Yoon</surname><given-names>J</given-names></name><name><surname>Michels</surname><given-names>GE</given-names></name><name><surname>Nilson</surname><given-names>A</given-names></name><name><surname>Sutor</surname><given-names>SL</given-names></name><name><surname>Platt</surname><given-names>JL</given-names></name><name><surname>Ansell</surname><given-names>SM</given-names></name><name><surname>von Bulow</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Selective activation of TACI by syndecan-2</article-title><source>Blood</source><year>2006</year><volume>107</volume><fpage>3235</fpage><lpage>3242</lpage><pub-id pub-id-type="pmid">16357320</pub-id><pub-id pub-id-type="doi">10.1182/blood-2005-01-0256</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rhodes</surname><given-names>DR</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Shanker</surname><given-names>K</given-names></name><name><surname>Deshpande</surname><given-names>N</given-names></name><name><surname>Varambally</surname><given-names>R</given-names></name><name><surname>Ghosh</surname><given-names>D</given-names></name><name><surname>Barrette</surname><given-names>T</given-names></name><name><surname>Pandey</surname><given-names>A</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name></person-group><article-title>Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression</article-title><source>Proc Natl Acad Sci USA</source><year>2004</year><volume>101</volume><fpage>9309</fpage><lpage>9314</lpage><pub-id pub-id-type="pmid">15184677</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0401994101</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Assou</surname><given-names>S</given-names></name><name><surname>Le Carrour</surname><given-names>T</given-names></name><name><surname>Tondeur</surname><given-names>S</given-names></name><name><surname>Strom</surname><given-names>S</given-names></name><name><surname>Gabelle</surname><given-names>A</given-names></name><name><surname>Marty</surname><given-names>S</given-names></name><name><surname>Nadal</surname><given-names>L</given-names></name><name><surname>Pantesco</surname><given-names>V</given-names></name><name><surname>Reme</surname><given-names>T</given-names></name><name><surname>Hugnot</surname><given-names>JP</given-names></name><etal></etal></person-group><article-title>A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas</article-title><source>Stem Cells</source><year>2007</year><volume>25</volume><fpage>961</fpage><lpage>973</lpage><pub-id pub-id-type="pmid">17204602</pub-id><pub-id pub-id-type="doi">10.1634/stemcells.2006-0352</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rhodes</surname><given-names>DR</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Shanker</surname><given-names>K</given-names></name><name><surname>Deshpande</surname><given-names>N</given-names></name><name><surname>Varambally</surname><given-names>R</given-names></name><name><surname>Ghosh</surname><given-names>D</given-names></name><name><surname>Barrette</surname><given-names>T</given-names></name><name><surname>Pandey</surname><given-names>A</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name></person-group><article-title>ONCOMINE: a cancer microarray database and integrated data-mining platform</article-title><source>Neoplasia (New York, NY)</source><year>2004</year><volume>6</volume><fpage>1</fpage><lpage>6</lpage></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brune</surname><given-names>V</given-names></name><name><surname>Tiacci</surname><given-names>E</given-names></name><name><surname>Pfeil</surname><given-names>I</given-names></name><name><surname>Doring</surname><given-names>C</given-names></name><name><surname>Eckerle</surname><given-names>S</given-names></name><name><surname>van Noesel</surname><given-names>CJ</given-names></name><name><surname>Klapper</surname><given-names>W</given-names></name><name><surname>Falini</surname><given-names>B</given-names></name><name><surname>von Heydebreck</surname><given-names>A</given-names></name><name><surname>Metzler</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis</article-title><source>J Exp Med</source><year>2008</year><volume>205</volume><fpage>2251</fpage><lpage>2268</lpage><pub-id pub-id-type="pmid">18794340</pub-id><pub-id pub-id-type="doi">10.1084/jem.20080809</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bredel</surname><given-names>M</given-names></name><name><surname>Bredel</surname><given-names>C</given-names></name><name><surname>Juric</surname><given-names>D</given-names></name><name><surname>Harsh</surname><given-names>GR</given-names></name><name><surname>Vogel</surname><given-names>H</given-names></name><name><surname>Recht</surname><given-names>LD</given-names></name><name><surname>Sikic</surname><given-names>BI</given-names></name></person-group><article-title>Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>8679</fpage><lpage>8689</lpage><pub-id pub-id-type="pmid">16204036</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-1204</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>French</surname><given-names>PJ</given-names></name><name><surname>Swagemakers</surname><given-names>SM</given-names></name><name><surname>Nagel</surname><given-names>JH</given-names></name><name><surname>Kouwenhoven</surname><given-names>MC</given-names></name><name><surname>Brouwer</surname><given-names>E</given-names></name><name><surname>Spek</surname><given-names>P van der</given-names></name><name><surname>Luider</surname><given-names>TM</given-names></name><name><surname>Kros</surname><given-names>JM</given-names></name><name><surname>Bent</surname><given-names>MJ van den</given-names></name><name><surname>Sillevis Smitt</surname><given-names>PA</given-names></name></person-group><article-title>Gene expression profiles associated with treatment response in oligodendrogliomas</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>11335</fpage><lpage>11344</lpage><pub-id pub-id-type="pmid">16357140</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-1886</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Hui</surname><given-names>AM</given-names></name><name><surname>Su</surname><given-names>Q</given-names></name><name><surname>Vortmeyer</surname><given-names>A</given-names></name><name><surname>Kotliarov</surname><given-names>Y</given-names></name><name><surname>Pastorino</surname><given-names>S</given-names></name><name><surname>Passaniti</surname><given-names>A</given-names></name><name><surname>Menon</surname><given-names>J</given-names></name><name><surname>Walling</surname><given-names>J</given-names></name><name><surname>Bailey</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain</article-title><source>Cancer Cell</source><year>2006</year><volume>9</volume><fpage>287</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">16616334</pub-id><pub-id pub-id-type="doi">10.1016/j.ccr.2006.03.003</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Diehn</surname><given-names>M</given-names></name><name><surname>Watson</surname><given-names>N</given-names></name><name><surname>Bollen</surname><given-names>AW</given-names></name><name><surname>Aldape</surname><given-names>KD</given-names></name><name><surname>Nicholas</surname><given-names>MK</given-names></name><name><surname>Lamborn</surname><given-names>KR</given-names></name><name><surname>Berger</surname><given-names>MS</given-names></name><name><surname>Botstein</surname><given-names>D</given-names></name><name><surname>Brown</surname><given-names>PO</given-names></name><etal></etal></person-group><article-title>Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme</article-title><source>Proc Natl Acad Sci USA</source><year>2005</year><volume>102</volume><fpage>5814</fpage><lpage>5819</lpage><pub-id pub-id-type="pmid">15827123</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0402870102</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krumbholz</surname><given-names>M</given-names></name><name><surname>Theil</surname><given-names>D</given-names></name><name><surname>Derfuss</surname><given-names>T</given-names></name><name><surname>Rosenwald</surname><given-names>A</given-names></name><name><surname>Schrader</surname><given-names>F</given-names></name><name><surname>Monoranu</surname><given-names>CM</given-names></name><name><surname>Kalled</surname><given-names>SL</given-names></name><name><surname>Hess</surname><given-names>DM</given-names></name><name><surname>Serafini</surname><given-names>B</given-names></name><name><surname>Aloisi</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma</article-title><source>J Exp Med</source><year>2005</year><volume>201</volume><fpage>195</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">15642740</pub-id><pub-id pub-id-type="doi">10.1084/jem.20041674</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tschen</surname><given-names>SI</given-names></name><name><surname>Stohlman</surname><given-names>SA</given-names></name><name><surname>Ramakrishna</surname><given-names>C</given-names></name><name><surname>Hinton</surname><given-names>DR</given-names></name><name><surname>Atkinson</surname><given-names>RD</given-names></name><name><surname>Bergmann</surname><given-names>CC</given-names></name></person-group><article-title>CNS viral infection diverts homing of antibody-secreting cells from lymphoid organs to the CNS</article-title><source>Eur J Immunol</source><year>2006</year><volume>36</volume><fpage>603</fpage><lpage>612</lpage><pub-id pub-id-type="pmid">16437540</pub-id><pub-id pub-id-type="doi">10.1002/eji.200535123</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>AL</given-names></name><name><surname>Wang</surname><given-names>ZC</given-names></name><name><surname>De Nicolo</surname><given-names>A</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Miron</surname><given-names>A</given-names></name><name><surname>Liao</surname><given-names>X</given-names></name><name><surname>Iglehart</surname><given-names>JD</given-names></name><name><surname>Livingston</surname><given-names>DM</given-names></name><name><surname>Ganesan</surname><given-names>S</given-names></name></person-group><article-title>X chromosomal abnormalities in basal-like human breast cancer</article-title><source>Cancer Cell</source><year>2006</year><volume>9</volume><fpage>121</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">16473279</pub-id><pub-id pub-id-type="doi">10.1016/j.ccr.2006.01.013</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Triadafilopoulos</surname><given-names>G</given-names></name><name><surname>Sahbaie</surname><given-names>P</given-names></name><name><surname>Young</surname><given-names>HS</given-names></name><name><surname>Omary</surname><given-names>MB</given-names></name><name><surname>Lowe</surname><given-names>AW</given-names></name></person-group><article-title>Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma</article-title><source>Gastroenterology</source><year>2006</year><volume>131</volume><fpage>925</fpage><lpage>933</lpage><pub-id pub-id-type="pmid">16952561</pub-id><pub-id pub-id-type="doi">10.1053/j.gastro.2006.04.026</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lenburg</surname><given-names>ME</given-names></name><name><surname>Liou</surname><given-names>LS</given-names></name><name><surname>Gerry</surname><given-names>NP</given-names></name><name><surname>Frampton</surname><given-names>GM</given-names></name><name><surname>Cohen</surname><given-names>HT</given-names></name><name><surname>Christman</surname><given-names>MF</given-names></name></person-group><article-title>Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data</article-title><source>BMC cancer</source><year>2003</year><volume>3</volume><fpage>31</fpage><pub-id pub-id-type="pmid">14641932</pub-id><pub-id pub-id-type="doi">10.1186/1471-2407-3-31</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Korkola</surname><given-names>JE</given-names></name><name><surname>Houldsworth</surname><given-names>J</given-names></name><name><surname>Chadalavada</surname><given-names>RS</given-names></name><name><surname>Olshen</surname><given-names>AB</given-names></name><name><surname>Dobrzynski</surname><given-names>D</given-names></name><name><surname>Reuter</surname><given-names>VE</given-names></name><name><surname>Bosl</surname><given-names>GJ</given-names></name><name><surname>Chaganti</surname><given-names>RS</given-names></name></person-group><article-title>Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>820</fpage><lpage>827</lpage><pub-id pub-id-type="pmid">16424014</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-2445</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blaveri</surname><given-names>E</given-names></name><name><surname>Simko</surname><given-names>JP</given-names></name><name><surname>Korkola</surname><given-names>JE</given-names></name><name><surname>Brewer</surname><given-names>JL</given-names></name><name><surname>Baehner</surname><given-names>F</given-names></name><name><surname>Mehta</surname><given-names>K</given-names></name><name><surname>Devries</surname><given-names>S</given-names></name><name><surname>Koppie</surname><given-names>T</given-names></name><name><surname>Pejavar</surname><given-names>S</given-names></name><name><surname>Carroll</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Bladder cancer outcome and subtype classification by gene expression</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>4044</fpage><lpage>4055</lpage><pub-id pub-id-type="pmid">15930339</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-2409</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Carbayo</surname><given-names>M</given-names></name><name><surname>Socci</surname><given-names>ND</given-names></name><name><surname>Lozano</surname><given-names>J</given-names></name><name><surname>Saint</surname><given-names>F</given-names></name><name><surname>Cordon-Cardo</surname><given-names>C</given-names></name></person-group><article-title>Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>778</fpage><lpage>789</lpage><pub-id pub-id-type="pmid">16432078</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2005.03.2375</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kimchi</surname><given-names>ET</given-names></name><name><surname>Posner</surname><given-names>MC</given-names></name><name><surname>Park</surname><given-names>JO</given-names></name><name><surname>Darga</surname><given-names>TE</given-names></name><name><surname>Kocherginsky</surname><given-names>M</given-names></name><name><surname>Karrison</surname><given-names>T</given-names></name><name><surname>Hart</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>KD</given-names></name><name><surname>Mezhir</surname><given-names>JJ</given-names></name><name><surname>Weichselbaum</surname><given-names>RR</given-names></name><etal></etal></person-group><article-title>Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>3146</fpage><lpage>3154</lpage><pub-id pub-id-type="pmid">15833844</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ginos</surname><given-names>MA</given-names></name><name><surname>Page</surname><given-names>GP</given-names></name><name><surname>Michalowicz</surname><given-names>BS</given-names></name><name><surname>Patel</surname><given-names>KJ</given-names></name><name><surname>Volker</surname><given-names>SE</given-names></name><name><surname>Pambuccian</surname><given-names>SE</given-names></name><name><surname>Ondrey</surname><given-names>FG</given-names></name><name><surname>Adams</surname><given-names>GL</given-names></name><name><surname>Gaffney</surname><given-names>PM</given-names></name></person-group><article-title>Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">14729608</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-2144</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Toruner</surname><given-names>GA</given-names></name><name><surname>Ulger</surname><given-names>C</given-names></name><name><surname>Alkan</surname><given-names>M</given-names></name><name><surname>Galante</surname><given-names>AT</given-names></name><name><surname>Rinaggio</surname><given-names>J</given-names></name><name><surname>Wilk</surname><given-names>R</given-names></name><name><surname>Tian</surname><given-names>B</given-names></name><name><surname>Soteropoulos</surname><given-names>P</given-names></name><name><surname>Hameed</surname><given-names>MR</given-names></name><name><surname>Schwalb</surname><given-names>MN</given-names></name><etal></etal></person-group><article-title>Association between gene expression profile and tumor invasion in oral squamous cell carcinoma</article-title><source>Cancer genetics and cytogenetics</source><year>2004</year><volume>154</volume><fpage>27</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">15381369</pub-id><pub-id pub-id-type="doi">10.1016/j.cancergencyto.2004.01.026</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alizadeh</surname><given-names>AA</given-names></name><name><surname>Eisen</surname><given-names>MB</given-names></name><name><surname>Davis</surname><given-names>RE</given-names></name><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Lossos</surname><given-names>IS</given-names></name><name><surname>Rosenwald</surname><given-names>A</given-names></name><name><surname>Boldrick</surname><given-names>JC</given-names></name><name><surname>Sabet</surname><given-names>H</given-names></name><name><surname>Tran</surname><given-names>T</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><etal></etal></person-group><article-title>Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling</article-title><source>Nature</source><year>2000</year><volume>403</volume><fpage>503</fpage><lpage>511</lpage><pub-id pub-id-type="pmid">10676951</pub-id><pub-id pub-id-type="doi">10.1038/35000501</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosenwald</surname><given-names>A</given-names></name><name><surname>Wright</surname><given-names>G</given-names></name><name><surname>Chan</surname><given-names>WC</given-names></name><name><surname>Connors</surname><given-names>JM</given-names></name><name><surname>Campo</surname><given-names>E</given-names></name><name><surname>Fisher</surname><given-names>RI</given-names></name><name><surname>Gascoyne</surname><given-names>RD</given-names></name><name><surname>Muller-Hermelink</surname><given-names>HK</given-names></name><name><surname>Smeland</surname><given-names>EB</given-names></name><name><surname>Giltnane</surname><given-names>JM</given-names></name><etal></etal></person-group><article-title>The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma</article-title><source>N Engl J Med</source><year>2002</year><volume>346</volume><fpage>1937</fpage><lpage>1947</lpage><pub-id pub-id-type="pmid">12075054</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa012914</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iacobuzio-Donahue</surname><given-names>CA</given-names></name><name><surname>Maitra</surname><given-names>A</given-names></name><name><surname>Olsen</surname><given-names>M</given-names></name><name><surname>Lowe</surname><given-names>AW</given-names></name><name><surname>van Heek</surname><given-names>NT</given-names></name><name><surname>Rosty</surname><given-names>C</given-names></name><name><surname>Walter</surname><given-names>K</given-names></name><name><surname>Sato</surname><given-names>N</given-names></name><name><surname>Parker</surname><given-names>A</given-names></name><name><surname>Ashfaq</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays</article-title><source>Am J Pathol</source><year>2003</year><volume>162</volume><fpage>1151</fpage><lpage>1162</lpage><pub-id pub-id-type="pmid">12651607</pub-id></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Freije</surname><given-names>WA</given-names></name><name><surname>Castro-Vargas</surname><given-names>FE</given-names></name><name><surname>Fang</surname><given-names>Z</given-names></name><name><surname>Horvath</surname><given-names>S</given-names></name><name><surname>Cloughesy</surname><given-names>T</given-names></name><name><surname>Liau</surname><given-names>LM</given-names></name><name><surname>Mischel</surname><given-names>PS</given-names></name><name><surname>Nelson</surname><given-names>SF</given-names></name></person-group><article-title>Gene expression profiling of gliomas strongly predicts survival</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>6503</fpage><lpage>6510</lpage><pub-id pub-id-type="pmid">15374961</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-0452</pub-id></citation></ref><ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Modlich</surname><given-names>O</given-names></name><name><surname>Prisack</surname><given-names>HB</given-names></name><name><surname>Pitschke</surname><given-names>G</given-names></name><name><surname>Ramp</surname><given-names>U</given-names></name><name><surname>Ackermann</surname><given-names>R</given-names></name><name><surname>Bojar</surname><given-names>H</given-names></name><name><surname>Vogeli</surname><given-names>TA</given-names></name><name><surname>Grimm</surname><given-names>MO</given-names></name></person-group><article-title>Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><fpage>3410</fpage><lpage>3421</lpage><pub-id pub-id-type="pmid">15161696</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-03-0134</pub-id></citation></ref><ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Farmer</surname><given-names>P</given-names></name><name><surname>Bonnefoi</surname><given-names>H</given-names></name><name><surname>Becette</surname><given-names>V</given-names></name><name><surname>Tubiana-Hulin</surname><given-names>M</given-names></name><name><surname>Fumoleau</surname><given-names>P</given-names></name><name><surname>Larsimont</surname><given-names>D</given-names></name><name><surname>Macgrogan</surname><given-names>G</given-names></name><name><surname>Bergh</surname><given-names>J</given-names></name><name><surname>Cameron</surname><given-names>D</given-names></name><name><surname>Goldstein</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Identification of molecular apocrine breast tumours by microarray analysis</article-title><source>Oncogene</source><year>2005</year><volume>24</volume><fpage>4660</fpage><lpage>4671</lpage><pub-id pub-id-type="pmid">15897907</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1208561</pub-id></citation></ref><ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ginestier</surname><given-names>C</given-names></name><name><surname>Cervera</surname><given-names>N</given-names></name><name><surname>Finetti</surname><given-names>P</given-names></name><name><surname>Esteyries</surname><given-names>S</given-names></name><name><surname>Esterni</surname><given-names>B</given-names></name><name><surname>Adelaide</surname><given-names>J</given-names></name><name><surname>Xerri</surname><given-names>L</given-names></name><name><surname>Viens</surname><given-names>P</given-names></name><name><surname>Jacquemier</surname><given-names>J</given-names></name><name><surname>Charafe-Jauffret</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Prognosis and gene expression profiling of 20q13-amplified breast cancers</article-title><source>Clin Cancer Res</source><year>2006</year><volume>12</volume><fpage>4533</fpage><lpage>4544</lpage><pub-id pub-id-type="pmid">16899599</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-2339</pub-id></citation></ref><ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bachtiary</surname><given-names>B</given-names></name><name><surname>Boutros</surname><given-names>PC</given-names></name><name><surname>Pintilie</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Bastianutto</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>JH</given-names></name><name><surname>Schwock</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Penn</surname><given-names>LZ</given-names></name><name><surname>Jurisica</surname><given-names>I</given-names></name><etal></etal></person-group><article-title>Gene expression profiling in cervical cancer: an exploration of intratumor heterogeneity</article-title><source>Clin Cancer Res</source><year>2006</year><volume>12</volume><fpage>5632</fpage><lpage>5640</lpage><pub-id pub-id-type="pmid">17020965</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-0357</pub-id></citation></ref><ref id="B57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mhawech-Fauceglia</surname><given-names>P</given-names></name><name><surname>Kaya</surname><given-names>G</given-names></name><name><surname>Sauter</surname><given-names>G</given-names></name><name><surname>McKee</surname><given-names>T</given-names></name><name><surname>Donze</surname><given-names>O</given-names></name><name><surname>Schwaller</surname><given-names>J</given-names></name><name><surname>Huard</surname><given-names>B</given-names></name></person-group><article-title>The source of APRIL up-regulation in human solid tumor lesions</article-title><source>J Leukoc Biol</source><year>2006</year><volume>80</volume><fpage>697</fpage><lpage>704</lpage><pub-id pub-id-type="pmid">16793914</pub-id><pub-id pub-id-type="doi">10.1189/jlb.1105655</pub-id></citation></ref><ref id="B58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mhawech-Fauceglia</surname><given-names>P</given-names></name><name><surname>Allal</surname><given-names>A</given-names></name><name><surname>Odunsi</surname><given-names>K</given-names></name><name><surname>Andrews</surname><given-names>C</given-names></name><name><surname>Herrmann</surname><given-names>FR</given-names></name><name><surname>Huard</surname><given-names>B</given-names></name></person-group><article-title>Role of the tumour necrosis family ligand APRIL in solid tumour development: Retrospective studies in bladder, ovarian and head and neck carcinomas</article-title><source>Eur J Cancer</source><year>2008</year><volume>44</volume><fpage>2097</fpage><lpage>2100</lpage><pub-id pub-id-type="pmid">18718755</pub-id><pub-id pub-id-type="doi">10.1016/j.ejca.2008.07.007</pub-id></citation></ref><ref id="B59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moreaux</surname><given-names>J</given-names></name><name><surname>Sprynski</surname><given-names>A-C</given-names></name><name><surname>Mahtouk</surname><given-names>K</given-names></name><name><surname>Moine</surname><given-names>P</given-names></name><name><surname>Robert</surname><given-names>N</given-names></name><name><surname>Rossi</surname><given-names>J-F</given-names></name><name><surname>Klein</surname><given-names>B</given-names></name></person-group><article-title>Binding of TACI and APRIL to Syndecan-1 Confer on Them a Major Role in Multiple Myeloma</article-title><source>ASH Annual Meeting Abstracts</source><year>2007</year><volume>110</volume><fpage>3522</fpage></citation></ref><ref id="B60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhan</surname><given-names>F</given-names></name><name><surname>Barlogie</surname><given-names>B</given-names></name><name><surname>Arzoumanian</surname><given-names>V</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Williams</surname><given-names>DR</given-names></name><name><surname>Hollmig</surname><given-names>K</given-names></name><name><surname>Pineda-Roman</surname><given-names>M</given-names></name><name><surname>Tricot</surname><given-names>G</given-names></name><name><surname>van Rhee</surname><given-names>F</given-names></name><name><surname>Zangari</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis</article-title><source>Blood</source><year>2007</year><volume>109</volume><fpage>1692</fpage><lpage>1700</lpage><pub-id pub-id-type="pmid">17023574</pub-id><pub-id pub-id-type="doi">10.1182/blood-2006-07-037077</pub-id></citation></ref><ref id="B61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Prasad</surname><given-names>M</given-names></name><name><surname>Lemon</surname><given-names>WJ</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Wright</surname><given-names>FA</given-names></name><name><surname>Kornacker</surname><given-names>K</given-names></name><name><surname>LiVolsi</surname><given-names>V</given-names></name><name><surname>Frankel</surname><given-names>W</given-names></name><name><surname>Kloos</surname><given-names>RT</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Gene expression in papillary thyroid carcinoma reveals highly consistent profiles</article-title><source>Proc Natl Acad Sci USA</source><year>2001</year><volume>98</volume><fpage>15044</fpage><lpage>15049</lpage><pub-id pub-id-type="pmid">11752453</pub-id><pub-id pub-id-type="doi">10.1073/pnas.251547398</pub-id></citation></ref><ref id="B62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dave</surname><given-names>SS</given-names></name><name><surname>Fu</surname><given-names>K</given-names></name><name><surname>Wright</surname><given-names>GW</given-names></name><name><surname>Lam</surname><given-names>LT</given-names></name><name><surname>Kluin</surname><given-names>P</given-names></name><name><surname>Boerma</surname><given-names>EJ</given-names></name><name><surname>Greiner</surname><given-names>TC</given-names></name><name><surname>Weisenburger</surname><given-names>DD</given-names></name><name><surname>Rosenwald</surname><given-names>A</given-names></name><name><surname>Ott</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Molecular diagnosis of Burkitt's lymphoma</article-title><source>N Engl J Med</source><year>2006</year><volume>354</volume><fpage>2431</fpage><lpage>2442</lpage><pub-id pub-id-type="pmid">16760443</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa055759</pub-id></citation></ref><ref id="B63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>M</given-names></name><name><surname>Ansell</surname><given-names>SM</given-names></name><name><surname>Witzig</surname><given-names>TE</given-names></name><name><surname>Ziesmer</surname><given-names>SC</given-names></name><name><surname>Cerhan</surname><given-names>JR</given-names></name><name><surname>Dillon</surname><given-names>SR</given-names></name><name><surname>Novak</surname><given-names>AJ</given-names></name></person-group><article-title>APRIL-TACI Interactions Mediate Non-Hodgkin Lymphoma B Cell Proliferation through Akt Regulated Cyclin D1 and P21</article-title><source>ASH Annual Meeting Abstracts</source><year>2007</year><volume>110</volume><fpage>3585</fpage></citation></ref><ref id="B64"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deshayes</surname><given-names>F</given-names></name><name><surname>Lapree</surname><given-names>G</given-names></name><name><surname>Portier</surname><given-names>A</given-names></name><name><surname>Richard</surname><given-names>Y</given-names></name><name><surname>Pencalet</surname><given-names>P</given-names></name><name><surname>Mahieu-Caputo</surname><given-names>D</given-names></name><name><surname>Horellou</surname><given-names>P</given-names></name><name><surname>Tsapis</surname><given-names>A</given-names></name></person-group><article-title>Abnormal production of the TNF-homologue APRIL increases the proliferation of human malignant glioblastoma cell lines via a specific receptor</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><fpage>3005</fpage><lpage>3012</lpage><pub-id pub-id-type="pmid">14691452</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1207350</pub-id></citation></ref><ref id="B65"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Okano</surname><given-names>H</given-names></name><name><surname>Shiraki</surname><given-names>K</given-names></name><name><surname>Yamanaka</surname><given-names>Y</given-names></name><name><surname>Inoue</surname><given-names>H</given-names></name><name><surname>Kawakita</surname><given-names>T</given-names></name><name><surname>Saitou</surname><given-names>Y</given-names></name><name><surname>Yamaguchi</surname><given-names>Y</given-names></name><name><surname>Enokimura</surname><given-names>N</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>Functional expression of a proliferation-related ligand in hepatocellular carcinoma and its implications for neovascularization</article-title><source>World J Gastroenterol</source><year>2005</year><volume>11</volume><fpage>4650</fpage><lpage>4654</lpage><pub-id pub-id-type="pmid">16094704</pub-id></citation></ref><ref id="B66"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Couchman</surname><given-names>JR</given-names></name></person-group><article-title>Syndecans: proteoglycan regulators of cell-surface microdomains?</article-title><source>Nat Rev Mol Cell Biol</source><year>2003</year><volume>4</volume><fpage>926</fpage><lpage>937</lpage><pub-id pub-id-type="pmid">14685171</pub-id><pub-id pub-id-type="doi">10.1038/nrm1257</pub-id></citation></ref><ref id="B67"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Filmus</surname><given-names>J</given-names></name></person-group><article-title>Glypicans in growth control and cancer</article-title><source>Glycobiology</source><year>2001</year><volume>11</volume><fpage>19R</fpage><lpage>23R</lpage><pub-id pub-id-type="pmid">11320054</pub-id><pub-id pub-id-type="doi">10.1093/glycob/11.3.19R</pub-id></citation></ref><ref id="B68"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mahtouk</surname><given-names>K</given-names></name><name><surname>Cremer</surname><given-names>FW</given-names></name><name><surname>Reme</surname><given-names>T</given-names></name><name><surname>Jourdan</surname><given-names>M</given-names></name><name><surname>Baudard</surname><given-names>M</given-names></name><name><surname>Moreaux</surname><given-names>J</given-names></name><name><surname>Requirand</surname><given-names>G</given-names></name><name><surname>Fiol</surname><given-names>G</given-names></name><name><surname>De Vos</surname><given-names>J</given-names></name><name><surname>Moos</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma</article-title><source>Oncogene</source><year>2006</year><volume>25</volume><fpage>7180</fpage><lpage>7191</lpage><pub-id pub-id-type="pmid">16732320</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1209699</pub-id></citation></ref><ref id="B69"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernfield</surname><given-names>M</given-names></name><name><surname>Gotte</surname><given-names>M</given-names></name><name><surname>Park</surname><given-names>PW</given-names></name><name><surname>Reizes</surname><given-names>O</given-names></name><name><surname>Fitzgerald</surname><given-names>ML</given-names></name><name><surname>Lincecum</surname><given-names>J</given-names></name><name><surname>Zako</surname><given-names>M</given-names></name></person-group><article-title>Functions of cell surface heparan sulfate proteoglycans</article-title><source>Annu Rev Biochem</source><year>1999</year><volume>68</volume><fpage>729</fpage><lpage>777</lpage><pub-id pub-id-type="pmid">10872465</pub-id><pub-id pub-id-type="doi">10.1146/annurev.biochem.68.1.729</pub-id></citation></ref><ref id="B70"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sasisekharan</surname><given-names>R</given-names></name><name><surname>Shriver</surname><given-names>Z</given-names></name><name><surname>Venkataraman</surname><given-names>G</given-names></name><name><surname>Narayanasami</surname><given-names>U</given-names></name></person-group><article-title>Roles of heparan-sulphate glycosaminoglycans in cancer</article-title><source>Nat Rev Cancer</source><year>2002</year><volume>2</volume><fpage>521</fpage><lpage>528</lpage><pub-id pub-id-type="pmid">12094238</pub-id><pub-id pub-id-type="doi">10.1038/nrc842</pub-id></citation></ref><ref id="B71"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Timar</surname><given-names>J</given-names></name><name><surname>Lapis</surname><given-names>K</given-names></name><name><surname>Dudas</surname><given-names>J</given-names></name><name><surname>Sebestyen</surname><given-names>A</given-names></name><name><surname>Kopper</surname><given-names>L</given-names></name><name><surname>Kovalszky</surname><given-names>I</given-names></name></person-group><article-title>Proteoglycans and tumor progression: Janus-faced molecules with contradictory functions in cancer</article-title><source>Semin Cancer Biol</source><year>2002</year><volume>12</volume><fpage>173</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">12083848</pub-id><pub-id pub-id-type="doi">10.1016/S1044-579X(02)00021-4</pub-id></citation></ref><ref id="B72"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alexander</surname><given-names>CM</given-names></name><name><surname>Reichsman</surname><given-names>F</given-names></name><name><surname>Hinkes</surname><given-names>MT</given-names></name><name><surname>Lincecum</surname><given-names>J</given-names></name><name><surname>Becker</surname><given-names>KA</given-names></name><name><surname>Cumberledge</surname><given-names>S</given-names></name><name><surname>Bernfield</surname><given-names>M</given-names></name></person-group><article-title>Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice</article-title><source>Nat Genet</source><year>2000</year><volume>25</volume><fpage>329</fpage><lpage>332</lpage><pub-id pub-id-type="pmid">10888884</pub-id><pub-id pub-id-type="doi">10.1038/77108</pub-id></citation></ref><ref id="B73"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klerk</surname><given-names>CP</given-names></name><name><surname>Smorenburg</surname><given-names>SM</given-names></name><name><surname>Otten</surname><given-names>HM</given-names></name><name><surname>Lensing</surname><given-names>AW</given-names></name><name><surname>Prins</surname><given-names>MH</given-names></name><name><surname>Piovella</surname><given-names>F</given-names></name><name><surname>Prandoni</surname><given-names>P</given-names></name><name><surname>Bos</surname><given-names>MM</given-names></name><name><surname>Richel</surname><given-names>DJ</given-names></name><name><surname>van Tienhoven</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>The effect of low molecular weight heparin on survival in patients with advanced malignancy</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>2130</fpage><lpage>2135</lpage><pub-id pub-id-type="pmid">15699479</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2005.03.134</pub-id></citation></ref></ref-list></back></article> 